Phase 3 study of durvalumab (MEDI4736) alone or in combination with tremelimumab versus standard of care (SoC) in platinum-resistant recurrent ormetastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): EAGLE

被引：0
|
作者：
Licitra, L. [1 ]
Even, C. [2 ]
Haddad, R. [3 ]
Tahara, M. [4 ]
Goswami, T. [5 ]
Franks, A. [6 ]
Emeribe, U. [7 ]
Jarkowski, A., III [5 ]
Melillo, G. [7 ]
Ferris, R. L. [8 ,9 ]
机构：
[1] Fdn IRCCS Inst Nazl Tumori, Head & Neck Canc Med Oncol Unit, Milan, Italy
[2] Inst Gustave Roussy, Head & Neck Oncol, Villejuif, France
[3] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[4] Natl Canc Ctr Hosp East, Head & Neck Med Oncol, Kashiwa, Chiba, Japan
[5] AstraZeneca, Immunooncol GMD, Gaithersburg, MD USA
[6] AstraZeneca, Clin Dev, Immunooncol, Gaithersburg, MD USA
[7] AstraZeneca, Global Med Dev, Gaithersburg, MD USA
[8] Univ Pittsburgh, Inst Canc, Dept Otolaryngol, Pittsburgh, PA USA
[9] Univ Pittsburgh, Inst Canc, Canc Immunol Program, Pittsburgh, PA USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
341TiP
引用
收藏
页码：101 / 101
页数：1
相关论文
共 50 条
  • [11] Phase Ib study of AVB-S6-500 (axl inhibition) in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (NCT04019288)
    Hinchcliff, Emily
    Gardiner, Elisabeth
    Westin, Shannon
    Bayer, Virginia
    Rangel, Kelly
    Lito, Kathryn
    Fellman, Bryan
    Yuan, Ying
    Sood, Anil
    Lu, Karen
    Jazaeri, Amir
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S166 - S167
  • [12] BIOMAb EGFRTM (Nimotuzumab/h-r3) in combination with standard of care in squamous cell carcinoma of head and neck (SCCHN)
    Reddy, B. K.
    Vidyasagar, M.
    Shenoy, K.
    Shenoy, A.
    Viswanath, L.
    Babu, G.
    Bapsy, P.
    Sathya, M.
    Srivastava, M.
    Nanjundappa
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S450 - S450
  • [13] Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/ metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment
    Jove, M.
    Brana, I.
    Oliva Bernal, M.
    Hernando Calvo, A.
    Erasun Lecuona, C.
    Assaf Pastrana, J. D.
    Mato-Berciano, A.
    V. Maliandi, M.
    Torres-Manjon, S.
    Moreno, R.
    Le, C.
    G. Nuciforo, P.
    Alemany, R.
    Capella, G.
    Blasco, C.
    Cascallo Piqueras, M.
    Mesia Nin, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S589 - S590
  • [14] Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment
    Jove, M.
    Brana, I.
    Oliva Bernal, M.
    Hernando Calvo, A.
    Erasun Lecuona, C.
    Assaf Pastrana, J. D.
    Mato-Berciano, A.
    Maliandi, M. V.
    Torres-Manjon, S.
    Moreno, R.
    Le, C.
    Nuciforo, P. G.
    Alemany, R.
    Capella, G.
    Blasco, C.
    Cascallo Piqueras, M.
    Mesia Nin, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S589 - S589
  • [15] Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE
    Mok, T.
    Schmid, P.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, C.
    Martin, C.
    Zhao, L.
    McIntosh, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
  • [16] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
  • [17] Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Fayette, J.
    Lefebvre, G.
    Posner, M. R.
    Bauman, J.
    Salas, S.
    Even, C.
    Saada-Bouzid, E.
    Seiwert, T.
    Colevas, D.
    Calmels, F.
    Zerbib, R.
    Chammard, A. Boyer
    Cohen, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 374 - 374
  • [18] A phase 3, randomized, open-label study of first-line durvalumab (MED14736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.
    Seiwert, Tanguy Y.
    Weiss, Jared
    Baxi, Shrujal S.
    Ahn, Myung-Ju
    Fayette, Jerome
    Gillison, Maura L.
    Machiels, Jean-Pascal H.
    Takahashi, Shunji
    Melillo, Giovanni
    Franks, April
    Emeribe, Ugochi
    Raben, David
    McDevitt, Michael
    Psyrri, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [19] Efficacy of Cetuximab Alone or in Combination With Docetaxel as Second-line Treatment in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Fekih, M.
    Ferrand, F. R.
    Saada, E.
    Hamdan, D.
    Desmaris, R.
    Schilf, A.
    Guigay, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S568 - S569
  • [20] MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC
    Peters, S.
    Antonia, S.
    Goldberg, S. B.
    Heymach, J. V.
    Kim, E. S.
    Nakagawa, K.
    Papadimitrakopoulou, V.
    Mukhopadhyay, P.
    McIntosh, S.
    Rizvi, N. A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S139 - S140
12345